Last updated on August 2019

RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

Brief description of study

The purpose of this study is to find out what effects, good and/or bad, a drug called durvalumab combined with Thyrogen-stimulated RAI, has on the patient and thyroid cancer. Durvalumab is a drug that has been developed to activate the immune system by blocking a protein called programmed death ligand-1 (PD-L1) that can be present on tumor and normal cells, including immune cells.

Clinical Study Identifier: NCT03215095

Find a site near you

Start Over

Memorial Sloan Kettering Commack

Commack, NY United States
  Connect »